Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Jiangchun Xu"'
Autor:
Xin Wang, Yan Li, Meng Sun, Jiping Zha, Songmao Zheng, Guizhong Liu, Peter Luo, John J Skinner, Kristine She, Jiangchun Xu, Felix Du
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/54d3ae910a7e49a8b32d88e170c68136
Autor:
Roland Schüle, Jochen Maurer, Toufike Kanouni, Jeffrey A. Stafford, Michael B. Wallace, Jiangchun Xu, Elmar Stickeler, Melanie Boerries, Marie Follo, Amelie Proske, Peter Bronsert, Nicola Iovino, Fides Zenk, Anita Allen, Dominica Willmann, Sylvia Urban, Bogdan-Tiberius Preca, Juliane Strietz, Stella S. Stepputtis, Eric Metzger
This file contains the legends to all Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5761318b1f6435dcbf3e792e5a2fa818
https://doi.org/10.1158/0008-5472.22419060.v1
https://doi.org/10.1158/0008-5472.22419060.v1
Autor:
Roland Schüle, Jochen Maurer, Toufike Kanouni, Jeffrey A. Stafford, Michael B. Wallace, Jiangchun Xu, Elmar Stickeler, Melanie Boerries, Marie Follo, Amelie Proske, Peter Bronsert, Nicola Iovino, Fides Zenk, Anita Allen, Dominica Willmann, Sylvia Urban, Bogdan-Tiberius Preca, Juliane Strietz, Stella S. Stepputtis, Eric Metzger
H3K9me3 levels increase upon treatment with QC6352. Changes in H3K9me3 levels are depicted according to genomic location.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03971b883243e51d248ae86c72123875
https://doi.org/10.1158/0008-5472.22419069
https://doi.org/10.1158/0008-5472.22419069
Autor:
Roland Schüle, Jochen Maurer, Toufike Kanouni, Jeffrey A. Stafford, Michael B. Wallace, Jiangchun Xu, Elmar Stickeler, Melanie Boerries, Marie Follo, Amelie Proske, Peter Bronsert, Nicola Iovino, Fides Zenk, Anita Allen, Dominica Willmann, Sylvia Urban, Bogdan-Tiberius Preca, Juliane Strietz, Stella S. Stepputtis, Eric Metzger
Traditional treatments for breast cancer fail to address therapy-resistant cancer stem–like cells that have been characterized by changes in epigenetic regulators such as the lysine demethylase KDM4. Here, we describe an orally available, selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::568147c1824ce1c828b615cb332bfec3
https://doi.org/10.1158/0008-5472.c.6510285.v1
https://doi.org/10.1158/0008-5472.c.6510285.v1
Autor:
Aaron Nguyen, Peng Zou, Songmao Zheng, Jianfeng Shi, Guizhong Liu, Yan Li, Felix Du, Peter Luo, Jiangchun Xu
Publikováno v:
Cancer Research. 83:2930-2930
Background: Anti-CD47 therapies have demonstrated promising clinical activities; however, expression of CD47 on many different normal human cell types, including RBCs, serves as a large antigen sink for anti-CD47 antibodies. Blocking CD47 on RBCs, su
Autor:
David J. Hosfield, Jiangchun Xu, Young K. Chen, Matt M. Kreilein, James Marvin Veal, Chon Lai, Christophe Severin, Toufike Kanouni, Stephen W. Kaldor, Lee N. Lawton, Robert Cho, Joselyn R. Del Rosario, Ryan Stansfield, Jeffrey A. Stafford, Natalie Y.-Y. Yuen, Shawn O’Connell, Paula Alessandra Tavares-Greco, Zhe Nie, Lihong Shi
Publikováno v:
Journal of Medicinal Chemistry. 63:14522-14529
Histone demethylase LSDl (KDMlA) belongs to the flavin adenine dinucleotide (FAD) dependent family of monoamine oxidases and is vital in regulation of mammalian biology. Dysregulation and overexpression of LSD1 are hallmarks of a number of human dise
Autor:
Guizhong Liu, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Bin Cai, Aaron N. Nguyen, Songmao Zheng, Jiangchun Xu, Yan Li, Felix Du, Peter Luo
Publikováno v:
Cancer Research. 82:2888-2888
Targeting CD28 for systemic T cell activation caused severe cytokine storm and multiorgan failure in an anti-CD28 antibody TGN1412 phase 1 trial. However, tumor specific CD28 targeting in a tumor associated antigen (TAA)×CD28 bispecific format, simi
Autor:
Guizhong Liu, Yan Li, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Linhai Qu, Aaron N. Nguyen, Songmao Zheng, Jiangchun Xu, Felix Du, Peter Luo
Publikováno v:
Cancer Research. 82:2869-2869
Bispecific T-cell engagers (TCEs) have shown therapeutic promise in treating hematologic cancers. However, their utility in treating solid tumors has yet to be effectively demonstrated due to on-target off-tumor toxicity and systemic cytokine release
Autor:
Bin Cai, Aaron N. Nguyen, Songmao Zheng, Jianfeng Shi, Guizhong Liu, Yan Li, Felix Du, Peter Luo, Jiangchun Xu
Publikováno v:
Cancer Research. 82:4257-4257
Anti-CD47 antibodies of the IgG4 isotype have shown promising activities in clinical trials for hematologic malignancies, mainly in the combination setting. To overcome the fundamental challenge of developing an anti-CD47 antibody of an active Fc iso
Autor:
Guizhong Liu, Zhengxi Dai, Jiagui Qu, Jianfeng Shi, Qi Zhao, Linhai Qu, Yan Li, Songmao Zheng, Jiangchun Xu, Felix Du, Peter Luo
Publikováno v:
Cancer Research. 82:2868-2868
Targeting CD137 by agonistic antibodies faces various challenges in the clinic. Utomilumab appears safe but has modest efficacy, while urelumab is more efficacious but causes severe dose-dependent liver toxicity. To unlock the full potential of CD137